Plant Name: Ligusticum tenuissimum
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.148E-08 | 1.231E-05 | CA1, CA12, CA2, CA5A, CA6, CA7, CA9, PPARA, PPARD, PPARG |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.942E-08 | 2.563E-05 | CYP2C19, CYP2C9, CYP2D6 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 6.917E-08 | 4.858E-05 | CYP2A6, CYP2C19, CYP2C9, CYP2D6 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 2.117E-07 | 1.317E-04 | FFAR4, NFKB1, PPARA, PPARD, PPARG |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 3.222E-07 | 1.896E-04 | CYP2A6, CYP2C19, CYP2C9 |
| BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 5.541E-07 | 3.175E-04 | CA2, CA9, FABP3, FFAR4, HPGD, NFKB1, PPARA, PPARG |
| MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 9.919E-07 | 5.143E-04 | CYP2A6, CYP2C19, CYP2C9 |
| BP | GO:0051179; localization | GO:0015908; fatty acid transport | 1.114E-06 | 5.390E-04 | FABP3, PPARA, PPARD, PPARG |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.092E-06 | 5.390E-04 | ALOX15, CYP2A6, CYP2C19, CYP2C9, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.934E-06 | 8.960E-04 | CYP2A6, CYP2C19, CYP2C9 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 4.066E-06 | 1.844E-03 | CA2, CA7 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 9.152E-06 | 3.436E-03 | CYP2A6, CYP2C19, CYP2C9, CYP2D6, PPARD |
| BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 1.353E-05 | 4.677E-03 | PPARA, PPARG |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.477E-05 | 5.027E-03 | CYP2A6, CYP2C19, CYP2C9, CYP2D6 |
| BP | GO:0051179; localization | GO:0010887; negative regulation of cholesterol storage | 2.028E-05 | 5.969E-03 | PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:0010871; negative regulation of receptor biosynthetic process | 2.028E-05 | 5.969E-03 | PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 2.028E-05 | 5.969E-03 | ALOX15, HPGD |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.025E-05 | 5.969E-03 | CYP2C19, CYP2C9, CYP2D6 |
| MF | GO:0005488; binding | GO:0050543; icosatetraenoic acid binding | 2.028E-05 | 5.969E-03 | FABP3, PPARG |
| MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 2.028E-05 | 5.969E-03 | CA1, CA2 |
| BP | GO:0051179; localization | GO:0051049; regulation of transport | 2.371E-05 | 6.793E-03 | ACHE, ALOX15, CA2, CA7, FFAR1, FFAR4, NFKB1, PPARA, PPARD, PPARG |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 2.622E-05 | 7.318E-03 | PPARA, PPARD, PPARG |
| BP | GO:0008152; metabolic process | GO:0009804; coumarin metabolic process | 2.838E-05 | 7.724E-03 | CYP2A6, CYP2D6 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 6.542E-21 | 1.425E-16 | CA1, CA12, CA14, CA2, CA5A, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.766E-16 | 1.923E-12 | CA1, CA12, CA14, CA2, CA5A, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.008E-14 | 4.389E-11 | CA1, CA12, CA2, CA5A, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.869E-20 | 1.495E-18 | CA12; CA1; CA2; CA5A; CA7; CA6; CA9; CA14 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.093E-06 | 2.915E-05 | CYP2C9; CYP2A6; CYP2D6; CYP2C19 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 1.093E-06 | 2.915E-05 | FABP3; PPARG; PPARA; PPARD |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 7.601E-06 | 1.216E-04 | CYP2C9; CYP2D6; ALOX15; CYP2C19 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 4.760E-06 | 9.521E-05 | CYP2C9; ALOX15; CYP2C19 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 4.807E-05 | 6.409E-04 | CYP2C9; ALOX15; CYP2C19 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 7.840E-05 | 8.960E-04 | CYP2C9; CYP2A6; CYP2D6 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.109E-04 | 1.109E-03 | CYP2C9; CYP2A6; CYP2C19 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.112E-03 | 9.885E-03 | HPGD; PPARG; NFKB1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.943E-03 | 1.554E-02 | NFKB1; PPARD |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 2.518E-03 | 1.831E-02 | CYP2C9; CYP2A6 |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 2.913E-03 | 1.942E-02 | PPARA; NFKB1 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 5.185E-03 | 3.191E-02 | PPARG; NFKB1 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.024E-02 | 4.550E-02 | PPARG; NFKB1; PPARD |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 6.910E-03 | 3.685E-02 | PPARA; NFKB1 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 9.989E-03 | 4.550E-02 | PPARG; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.118E-02 | 4.707E-02 | LMNA; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.013E-02 | 4.550E-02 | PPARA; NFKB1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 5.737E-03 | 3.278E-02 | CYP2A6 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| C00-D49: Neoplasms | Cancer | C00-C96 | CA1; CA9; NFKB1; ACHE |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; ACHE; ACHE; PPARG; PPARG |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | PPARG |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; NFKB1; PPARD; PPARG; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; CYP2D6 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PPARG |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; ACHE |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| NA: NA | Dyslipidemia | NA | PPARD |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |